Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The MSL in CANADA vs. the US MSL
Summary
In this episode, Claudia Barube and Jeffrey Vaughn join Tom Caravela to explore the unique challenges and opportunities for Medical Science Liaisons (MSLs) in Canada. The discussion covers the transition from sales roles to MSL positions, with insights on differing responsibilities and territories between Canada and the US. Claudia shares her experiences working with Health Canada, addressing language and logistical challenges faced by Canadian MSLs. The episode delves into strategies for engaging Key Opinion Leaders (KOLs) across large territories and compares virtual versus live engagements. Claudia and Jeffrey offer advice for aspiring MSLs, emphasizing best practices and strategic accomplishments.
My guests today are Claudia Bérubé, Medical Science Liaison Quebec and Jeffrey Vaughan, National Director MSLs both at Ashfield, we discuss her career story and what it is like to be an MSL in Canada vs. the US.
_This episode is sponsored by Ashfield Engage, part of Inizio Engage, is a commercialization and strategic engagement partner for the healthcare industry, delivering solutions to meet the needs of patients, providers, payers, and pharmaceutical companies to improve the treatment experience and outcomes. Ashfield Engage creates personalized, impactful experiences and delivers and average of 5 million engagements annually across all healthcare stakeholders. For more information, please visit https://ashfieldengage.com/
_Claudia discusses….
π Her career journey and transition into industry
π What it is like to be an MSL in Canada
π How medical affairs and drug development differs in Canada
π Current challenges she faces as an MSL
π Advice to other MSLs and those looking to transition into the role
MSL Canada, Medical Science Liaisons, Key Opinion Leaders, Health Canada, MSL career advice
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary